Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex

Abstract excerpt

Rapamycin inhibits the mTOR (target of rapamycin) pathway and extends lifespan in multiple species. The tuberous sclerosis complex (TSC) protein is a negative regulator of mTOR. In humans, loss of the TSC protein results in a disorder characterized clinically by the growth of benign tumors in multiple organs, due to overactivation of mTOR inhibition. Subependymal giant cell astrocytomas (SEGAs) are benign brain...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Histiocytic Disorders and Treatments
• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Tuberous Sclerosis Complex Research